Transforming growth factor-beta1 stimulates degranulation and oxidant release by adherent human neutrophils.
The signal transduction pathways that are activated by cytokines and growth factors binding to their receptors on human neutrophils (PMN) are poorly understood. When PMN in suspension encounter many of these agonists they are not activated, but rather are primed for subsequent activation. We and others reported that when PMN are plated onto fibrinogen and stimulated with cytokines or with the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP) they respond by releasing hydrogen peroxide (H202) and the specific granule component lactoferrin. Transforming growth factor-beta1 (TGF-beta1) is released by many cells including PMN. It has been reported that TGF-beta1 stimulates chemotaxis but not exocytosis or superoxide production by cells in suspension. We hypothesized that TGF-beta1 would activate PMN to release H202 when they were adherent to fibrinogen, a response mediated by beta2++integrin receptors. In this study, we determined whether TGF-beta1 stimulated H202 and lactoferrin release by PMN adherent to fibrinogen. TGF-beta1 stimulated H202 and lactoferrin release from adherent PMN in a concentration-dependent manner, with effects seen in the range of 0.1 to 100 pg/mL. Both H202 and lactoferrin release were detected by 60 min and continued for at least 180 min. Adhesion and spreading of PMN paralleled H202 and lactoferrin release. Ethanol (200 mM) blocked both H202 and lactoferrin release, suggesting the involvement of the phospholipase D pathway. In PMN labeled with lyso-[3H]phosphatidylcholine, we observed that TGF-beta1 treatment caused an increase in [3H]phosphatidate. Propranolol (150 microM), an inhibitor of phosphatidate phosphohydrolase, blocked both H202 and lactoferrin release, suggesting that the conversion of phosphatidic acid to diradylglycerol is an important step in PMN activation by TGF-beta1. Overall, these results are similar to those reported for fMLP activation of adherent PMN and suggest that a common pathway is involved in both chemoattractant and cytokine activation.
Balazovich
K J
KJ
Department of Pediatrics, University of Michigan School of Medicine, Ann Arbor 48109-0238, USA.
Fernandez
R
R
Hinkovska-Galcheva
V
V
Suchard
S J
SJ
Boxer
L A
LA
D000440:Butanols / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects; D015550:Cell Degranulation / Q000187:drug effects*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D000431:Ethanol / Q000494:pharmacology; D005340:Fibrinogen; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D007781:Lactoferrin / Q000378:metabolism; D016177:Macrophage-1 Antigen / Q000502:physiology; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000502:physiology*; D010712:Phosphatidic Acids / Q000378:metabolism; D011433:Propranolol / Q000494:pharmacology; D017382:Reactive Oxygen Species / Q000378:metabolism*; D015398:Signal Transduction; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
D000440:Butanols; D016177:Macrophage-1 Antigen; D010712:Phosphatidic Acids; D017382:Reactive Oxygen Species; D016212:Transforming Growth Factor beta; D000431:Ethanol; D009240:N-Formylmethionine Leucyl-Phenylalanine; D005340:Fibrinogen; D011433:Propranolol; D006861:Hydrogen Peroxide; D007781:Lactoferrin